News

The grant competition attracted 3,928 proposals, marking a 13% increase in demand from 2024’s opening call.

Researchers at Osaka University have identified two transcription factors that contribute to the development of gut-resident memory T cells associated with Crohn’s disease, a chronic inflammatory disorder affecting the digestive tract.

Medicines containing a type of PFAS or ‘forever chemical’ called fluorine are not leading to higher numbers of adverse drug reactions according to new data analysis.

Scientists have discovered that the body’s immune system strongly reacts to an internal protein from SARS-CoV-2, the virus that causes COVID-19, which mutates less frequently than the surface-spike protein currently targeted by vaccines.

Researchers have created a protein-based therapeutic tool that could change the way we treat diseases caused by harmful or unnecessary cells by offering targeted removal.

German researchers developed a therapeutic HPV vaccine using silica nanoparticles loaded with viral protein fragments. In humanized mouse models, the vaccine activated cytotoxic T cells, suppressed HPV-positive tumors and improved survival.

Zeaxanthin, known for protecting vision, also strengthens the cancer-fighting activity of immune cells, highlighting its potential as a supplement to improve immunotherapy effectiveness.

Research shows the whole PEPITEM molecule not only reduces bone resorption and increases bone formation, but also promotes angiogenesis (the growth of capillaries from pre-existing blood vessels) in bone.

An organoid platform has been designed to enable accurate assessment of antibodies and vaccines against SARS-CoV-2.

By focusing on a small number of binder designs, rather than high-throughput screening of vast libraries of candidates, BindCraft has the potential to make protein design more efficient as well as more democratized.